Discover 118 paid clinical trials in Missoula, Montana. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Filter
2
Filter results
Results: 118
Active & Responsive
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer
for
Anatomic Stage I Breast Cancer AJCC v8,
Location: Missoula MT, Anaconda MT, Kalispell MT, Great Falls MT,
Sponsor: SWOG Cancer Research Network
Sex: All
Age: 18+
Code: NCT05929768
Phase3, Recruiting
Active & Responsive
Evaluating Whether an Educational Website Called Current Together After Cancer (CTAC) Improves Follow-up Care for Colorectal Cancer Survivors
for
Colorectal Cancer Stage II, Colorectal Cancer Stage III
Location: Missoula MT, Anaconda MT, Kalispell MT, Helena MT,
Sponsor: SWOG Cancer Research Network
Sex: All
Age: 18+
Code: NCT07018869
Phase3, Recruiting
Active & Responsive
Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
Testing an Enhanced Digital Delivery Model for Inherited Cancer Genetic Testing in Young Adults With Cancer
for
Miscellaneous Neoplasm, Nos, Non-Neoplastic Condition, Nos
Location: Missoula MT, Anaconda MT, Kalispell MT, Helena MT,
Sponsor: Alliance for Clinical Trials in Oncology
Sex: All
Age: 18+
Code: NCT07091617
Recruiting
Active & Responsive
Mechanisms of Change in Behavioral Cough Suppression Therapy for Refractory Chronic Cough
for
Chronic Cough (CC), Refractory Chronic Cough,
Location: Missoula MT, Atlanta GA
Sponsor: University of Montana
Sex: All
Age: 18 - 70+
Code: NCT06960759
Phase2, Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
Active & Responsive
Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)
for
Obesity or Overweight
Location: Missoula MT, Meridian ID, Redmond WA, Las Vegas NV,
Sponsor: Amgen
Sex: All
Age: 18 - 70+
Code: NCT07575399
Phase3, Recruiting
Active & Responsive
A Randomized Comparison of Stage-Based Care Versus Risk Factor-Based Care for Prevention of Cardiovascular Events
for
Diabetes Mellitus, Type 2, PreDiabetes, Metabolic Syndrome
Location: Missoula MT, Kalispell MT, Meridian ID, Everett WA,
Sponsor: Cleerly, Inc.
Sex: All
Age: 55+
Code: NCT06112418
Recruiting
Active & Responsive
BEATRIX: A Study to Learn About a Group B Streptococcus Vaccine in Healthy Pregnant Women and Their Babies
for
Healthy
Location: Missoula MT, Great Falls MT, Rexburg ID, Garden City ID,
Sponsor: Pfizer
Sex: All
Age: 0 - 49
Code: NCT07160244
Phase3, Recruiting
Active & Responsive
Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
Location: Missoula MT, Anaconda MT, Kalispell MT, Great Falls MT,
Sponsor: National Cancer Institute (NCI)
Sex: Female
Age: 18+
Code: NCT07198074
Phase3, Recruiting
Active & Responsive
Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas
for
Metastatic Dedifferentiated Liposarcoma,
Location: Missoula MT, Anaconda MT, Kalispell MT, Great Falls MT,
Sponsor: National Cancer Institute (NCI)
Sex: All
Age: 18+
Code: NCT06422806
Phase3, Recruiting
Active & Responsive
Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial
for
Advanced Esophageal Adenocarcinoma,
Location: Missoula MT, Anaconda MT, Kalispell MT, Great Falls MT,
Sponsor: National Cancer Institute (NCI)
Sex: All
Age: 18+
Code: NCT06203600
Phase2, Phase3, Recruiting
Active & Responsive
BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
for
Clinical Stage III Cutaneous Melanoma AJCC v8,
Location: Missoula MT, Anaconda MT, Kalispell MT, Great Falls MT,
Sponsor: National Cancer Institute (NCI)
Sex: All
Age: 18+
Code: NCT05136196
Phase2, Recruiting
Active & Responsive
Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma
for
Recurrent Head and Neck Squamous Cell Carcinoma,
Location: Missoula MT, Kalispell MT, Great Falls MT, Portland OR,
Sponsor: National Cancer Institute (NCI)
Sex: All
Age: 18 - 70+
Code: NCT04671667
Phase2, Recruiting
Active & Responsive
Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays
for
Ampulla of Vater Carcinoma, Appendix Carcinoma,
Location: Missoula MT, Anaconda MT, Kalispell MT, Helena MT,
Sponsor: Alliance for Clinical Trials in Oncology
Sex: All
Age: 18+
Code: NCT07283939
Recruiting
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
for
Anatomic Stage II Breast Cancer AJCC v8,
Location: Coeur d'Alene ID, Post Falls ID, Sandpoint ID,
Sponsor: National Cancer Institute (NCI)
Sex: All
Age: 18+
Code: NCT06058377
Phase3, Recruiting
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
for
Fallopian Tube Endometrioid Adenocarcinoma,
Location: Missoula MT, Anaconda MT, Kalispell MT, Great Falls MT,
Location: Missoula MT, Anaconda MT, Kalispell MT, Great Falls MT,
Sponsor: National Cancer Institute (NCI)
Sex: Female
Age: 18+
Code: NCT05256225
Phase3, Recruiting
Family Communications After Genetic Testing
for
Colon Adenocarcinoma, Colorectal Adenocarcinoma,
Location: Missoula MT, Anaconda MT, Kalispell MT, Helena MT,
Sponsor: Alliance for Clinical Trials in Oncology
Sex: All
Age: 18+
Code: NCT07143487
Recruiting
Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy